Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High Dose BEAM for Non-Hodgkin Lymphoma: The Role of Histology

Standard-dose (90)yttrium-ibritumomab tiuxetan (0.4 mci/kg) (Zevalin) together with high-dose BEAM (BCNU, etoposide, cytarabine, and melphalan) (Z-BEAM) has been shown to be a well-tolerated autologous hematopoietic stem cell transplantation (autoHCT) preparative regimen for non-Hodgkin lymphoma. We...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Biol Blood Marrow Transplant
Main Authors: Krishnan, Amrita Y., Palmer, Joycelynne, Nademanee, Auayporn P., Chen, Robert, Popplewell, Leslie L., Tsai, Ni-Chun, Sanchez, James F., Simpson, Jennifer, Spielberger, Ricardo, Yamauchi, Dave, Forman, Stephen J.
Formato: Artigo
Idioma:Inglês
Publicado: 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5646666/
https://ncbi.nlm.nih.gov/pubmed/28267593
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2017.03.004
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares